Please select a Capability in order to start your service request.
Commitments include cash and product donations through AmeriCares, Direct Relief, Heart to Heart International, Project HOPE, Save the Children and UNICEFFeb 26, 2015
SAN JOSE, CA, Feb. 26, 2015 – BD Life Sciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Cellular Research, an innovative company focused on enabling high-resolution biology, today announced that they will be jointly promoting their unique solutions for highly multiplexed cell isolation and single-cell gene expression analysis.
The companies are promoting BD’s powerful BD FACS™ single-cell sorting instrumentation and software with Cellular Research’s Precise™ assays based on Molecular Indexing™ technology to offer customers an integrated workflow for measuring both nucleic acid and protein expression in cellular subtypes.
“We believe that this combination of unique capabilities, Molecular Indexing of genetic markers from Cellular Research and single-cell sorting using protein markers from BD, will significantly increase the ability to identify and analyze cell populations for basic and clinical research,” said Stephen Fodor, Ph.D., Chief Executive Officer of Cellular Research.
Cellular Research has developed Precise, a highly multiplexed molecular and sample barcoding technology, whereby each transcript in each plated cell is uniquely barcoded during incorporation into one sequencing library. Precise encoding plates can also be multiplexed, enabling up to 4,608 single cells to be prepared into one single sequencing library and reaction.
The combined workflow enables cells to be individually sorted into 96- or 384- well Precise encoding plates using the BD FACS™ instruments and software. “Today’s announcement represents an exciting step forward for researchers engaged in single-cell genomic analysis” said Claude Dartiguelongue, Worldwide President, BD Biosciences. “The efficiency of identifying and isolating single cells greatly increases the throughput of cells available for transcriptome analysis, creating the potential, now within reach of investigators, to analyze gene expression targets in many thousands of individual cells.”
Initial results and findings will be presented during the 16th annual Advances in Genome Biology and Technology (AGBT) meeting held in Marco Island, Florida, February 25-28. The presentation is titled: “A Comprehensive High Throughput Single Cell Analysis Workflow Combining Proteomic and Genomic Information: Flow sorting, single cell tagging, molecular barcoding, library preparation, and sequencing analysis.”
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
For more information on BD, please visit bd.com.